Intelligent Bio Solutions

Intelligent Bio Solutions Net Debt/Equity

The Net Debt to Equity Ratio of Intelligent Bio Solutions (INBS) as of Oct 21, 2026 is -0.39. In the previous year, Net Debt to Equity Ratio was -0.25 — a change of 60.07% (lower).

Net Debt/Equity

-0.39

YoY

60.07%

Last updated:

Net Debt to Equity Ratio of Intelligent Bio Solutions is 2026 -0.39 . Net Debt to Equity Ratio of Intelligent Bio Solutions was 2025 -0.25 . It decreases by 60.07% lower compared to the previous year.

The Intelligent Bio Solutions Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2018
-1.01 USD
Jan 1, 2019
-1.07 USD
Jan 1, 2020
-0.91 USD
Jan 1, 2021
-0.83 USD
Jan 1, 2023
0.10 USD
Jan 1, 2024
-0.62 USD
Jan 1, 2025
-0.25 USD
Jan 1, 2026
-0.39 USD
The Intelligent Bio Solutions Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.39+60.07%
-0.25-60.22%
-0.62-722.26%
0.10-112.05%
-0.83-8.99%
-0.91-15.11%
-1.07+5.79%
-1.01+71.77%
-0.59—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Intelligent Bio Solutions Stock analysis

What does Intelligent Bio Solutions do? Intelligent Bio Solutions, Inc. generates revenue through its Commercially available Intelligent Fingerprinting Products (IFPG) segment, which includes a portable drug screening system analyzing fingerprint sweat via a one-time cartridge and handheld reader. The company also develops diagnostic tests under the Development Stage Saliva Glucose Biosensor Platform (SGBP), targeting diabetic patients with a non-invasive saliva glucose biosensor (SGB) intended to replace finger-prick blood monitoring. Its biosensor platform supports multiple biological analyte detection for point-of-care diagnostic tests (POCT) in clinical chemistry, immunology, tumor markers, allergens, and endocrinology. The firm serves primary health practitioners and patients seeking non-invasive monitoring solutions. The company's product portfolio features the IFPG segment's portable drug screening system, which is sold to healthcare providers and law enforcement agencies for rapid drug testing. The SGBP segment focuses on developing the Saliva Glucose Biosensor (SGB), a point-of-care diagnostic test expected to address the needs of diabetic patients requiring frequent glucose monitoring without invasive procedures. The biosensor platform enables detection of multiple analytes, expanding the company's offerings in clinical chemistry and related diagnostic fields. Intelligent Bio Solutions, Inc. targets primary health practitioners and patients as key segments for its non-invasive diagnostic solutions. The IFPG segment's portable drug screening system is designed for use in clinical and law enforcement settings, while the SGBP segment's Saliva Glucose Biosensor aims to provide a convenient alternative to traditional blood glucose monitoring for diabetic patients. The company's development stage products focus on replacing invasive methods with real-time, non-invasive monitoring technologies. Intelligent Bio Solutions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intelligent Bio Solutions stock

Net Debt to Equity Ratio of Intelligent Bio Solutions is -0.39 in 2026.

Net Debt to Equity Ratio of Intelligent Bio Solutions changed from -0.25 to -0.39, representing a 60.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Intelligent Bio Solutions since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Intelligent Bio Solutions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Intelligent Bio Solutions

All Key Metrics — Intelligent Bio Solutions